Discrepancies in predicted fracture risk in elderly people

BMJ (Online)

Volumn 346, Issue 7892, 2013, Pages

  Bolland, Mark J ^a   Jackson, Rod ^a   Gamble, Greg D ^a   Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLEDRONIC ACID;

ACCURACY; AGE DISTRIBUTION; ARTICLE; BODY MASS; BONE DENSITY; CALCULATOR; DRUG EFFICACY; FRACTURE; FRACTURE RISK CALCULATOR; FRAGILITY FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; MORTALITY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; FEMALE; FRACTURES, BONE; HUMANS; MALE; RISK; RISK ASSESSMENT;

EID: 84873048356     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e8669     Document Type: Article

References (19)

1. Ensrud KE, Lui LY, Taylor BC, Schousboe JT, Donaldson MG, Fink HA, et al. A comparison of prediction models for fractures in older women: is more better? Arch Intern Med 2009;169:2087-94.
2. Bolland MJ, Siu AT, Mason BH, Horne AM, Ames RW, Grey AB, et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 2011;26:420-7.
3. Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFracture scores. BMJ 2011;342:d3651.
4. Langsetmo L, Nguyen TV, Nguyen ND, Kovacs CS, Prior JC, Center JR, et al. Independent external validation of nomograms for predicting risk of low-trauma fracture and hip fracture. CMAJ 2011;183:E107-14.
5. Steurer J, Haller C, Hauselmann H, Brunner F, Bachmann LM. Clinical value of prognostic instruments to identify patients with an increased risk for osteoporotic fractures: systematic review. PLoS One 2011;6:e19994.
6. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
7. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
8. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
9. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long? N Engl J Med 2012;366:2051-3.
10. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc 2010;58:783-7.
11. Singer BR, McLauchlan GJ, Robinson CM, Christie J. Epidemiology of fractures in 15, 000 adults: the influence of age and gender. J Bone Joint Surg Br 1998;80:243-8.
12. Melton LJ 3rd, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 1999;9:29-37.
13. Poses RM, Smith WR, McClish DK, Huber EC, Clemo FL, Schmitt BP, et al. Physicians' survival predictions for patients with acute congestive heart failure. Arch Intern Med 1997;157:1001-7.
14. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003;327:195-8.
15. Siontis GC, Tzoulaki I, Ioannidis JP. Predicting death: an empirical evaluation of predictive tools for mortality. Arch Intern Med 2011;171:1721-6.
16. Dawson-Hughes B. A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 2008;93:2463-5.
17. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009;62:105-8.
18. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-408.
19. Bolland MJ, Grey A. Disparate outcomes from applying UK and US osteoporosis treatment guidelines. J Clin Endocrinol Metab 2010;95:1856-60.